SRSF2 mutant MDS and AML PDX models showed a significant response to CTX-712, with many mice achieving complete remission [82], prompting the initiation of a currently ongoing multicenter, single-arm dose, phase I clinical trial for patients with hematologic malignancy (NCT05732103) [83]. This evidence concerns the gene SRSF2 and myelodysplastic syndrome.